Accelerate Diagnostics Inc. (NASDAQ:AXDX) saw an upside of 12.25% to close Tuesday at $6.23 after adding $0.68 on the day. The 5-day average trading volume is 584,060 shares of the company’s common stock. It has gained $6.39 in the past week. An average of 415,535 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 261,276.
AXDX’s 1-month performance is 4.36% or $0.19 on its low of $5.15 reached on 09/27/21. The company’s shares have touched a 52-week low of $5.15 and high of $15.60, with the stock’s rally to the 52-week high happening on 01/27/21. YTD, AXDX has lost -17.81% or -$1.35. However, the current price is down -60.06%% from the 52-week high price.
A Backdoor Way To Profit From Today’s Crypto Bull Market
In any crypto bull market, there's a lot of money to be made.
But what if we told you the best opportunities are not cryptocurrencies themselves… but instead, simply crypto stocks?
This strategy is simply and ridiculously easy.
Here are 6 ways to gain exposure to crypto outside the norm. This is arguably the safest bet you can make.
On Jun 22, 113 days have gone by since the last insider trading activity for Accelerate Diagnostics Inc. (AXDX). Phillips Jack (Chief Executive Officer) most recently sold 23,479 shares at $7.94 per share on Jun 22. This transaction cost the insider $186,423. Chief Financial Officer, REICHLING STEVEN, sold 8,303 shares at a price of $6.76 on May 13. Then, on May 13, Head of Commercial Operations Price Ron sold 6,282 shares at a price of $6.76 per share. This transaction amounted to $42,466.
Accelerate Diagnostics Inc. (AXDX) has a trailing price-to-earnings (P/E) ratio of 26.50 for the broader industry and 32.19 for the sector.AXDX stock has a beta of 1.84. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 32.10.
Accelerate Diagnostics Inc.’s quick ratio for the period ended June 29 was 8.00, with the current ratio over the same period at 9.00 meaning that AXDX stock is able to fulfill its debt obligations. In terms of profitability, the gross margin trailing 12 months is 36.60%. The trailing 12-month EBITDA margin is -543.69%. The firm’s gross profit as reported stood at $4.46 million against revenue of $11.16 million.
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 23.93% to $2.8 million, while revenue of $2.52 million was 10.0% off the previous quarter. Analysts expected AXDX to announce -$0.33 per share in earnings in its latest quarter, but it posted -$0.36, representing a -9.10% surprise. EBITDA for the quarter stood at more than -$13.87 million. AXDX stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 163.74 million, with total debt at $155.91 million. Shareholders hold equity totaling $61.5 million
Let’s look briefly at Accelerate Diagnostics Inc. (AXDX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 12 October was 65.32% to suggest the stock is trending Neutral, with historical volatility in this time period at 74.88%.
The stock’s 5-day moving average is $5.72, reflecting a +12.66% or $0.70 change from its current price. AXDX is currently trading +4.53% above its 20-day SMA, -13.83% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -13.95% and -19.51% respectively.
Stochastic %K and %D was 57.51% and 48.73% and the average true range (ATR) pointed at 0.40. The RSI (14) points at 58.16%, while the 14-day stochastic is at 87.10% with the period’s ATR at 0.38. The stock’s 9-day MACD Oscillator is pointing at 0.09 and 0.14 on the 14-day charts.
In the most recent analyst report for Accelerate Diagnostics Inc. (NASDAQ: AXDX), BTIG Research launched coverage with a Neutral rating. Analysts offering their rating for AXDX stock have a consensus rating for the stock as Hold. Currently, 1 brokerage advisors rate AXDX as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 2 have offered a “buy” rating.
What is AXDX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $7.00 and a high of $15.00, with their median price target at $11.00. Looking at these predictions, the average price target given by analysts is for Accelerate Diagnostics Inc. (AXDX) stock is $11.00.